Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Change in Receivables (2018 - 2025)

Precision Biosciences (DTIL) has disclosed Change in Receivables for 8 consecutive years, with -$4000.0 as the latest value for Q4 2025.

  • Quarterly Change in Receivables fell 109.76% to -$4000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$229000.0 through Dec 2025, up 65.92% year-over-year, with the annual reading at -$229000.0 for FY2025, 65.92% up from the prior year.
  • Change in Receivables for Q4 2025 was -$4000.0 at Precision Biosciences, down from $4000.0 in the prior quarter.
  • The five-year high for Change in Receivables was $9.3 million in Q1 2021, with the low at -$49.8 million in Q3 2022.
  • Average Change in Receivables over 5 years is -$3.8 million, with a median of -$22500.0 recorded in 2023.
  • The sharpest move saw Change in Receivables soared 220.08% in 2021, then plummeted 51940.0% in 2023.
  • Over 5 years, Change in Receivables stood at -$18.8 million in 2021, then skyrocketed by 100.03% to $5000.0 in 2022, then tumbled by 51940.0% to -$2.6 million in 2023, then surged by 101.58% to $41000.0 in 2024, then crashed by 109.76% to -$4000.0 in 2025.
  • According to Business Quant data, Change in Receivables over the past three periods came in at -$4000.0, $4000.0, and -$4000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.